Development of a high-throughput screen to identify small molecule enhancers of sarcospan for the treatment of Duchenne muscular dystrophy

• Published in: Skeletal muscle Vol. 9; no. 1; p. 32
• Main Authors: Shu, Cynthia, Kaxon-Rupp, Ariana N, Collado, Judd R, Damoiseaux, Robert, Crosbie, Rachelle H
• Format: Journal Article
• Language: English
• Published: England BioMed Central 12.12.2019; BMC
• Subjects: Age; Antagonists; C2C12; Calcium antagonists; Calcium channels (L-type); Cardiomyocytes; Cell adhesion; Cell differentiation; Cloning; Cytoskeleton; Deoxyribonucleic acid; Disease; DNA; Drug discovery; Duchenne muscular dystrophy; Duchenne's muscular dystrophy; Dystrophin; Enhancers; Extracellular matrix; Felodipine; Gene expression; Genomes; Glycoproteins; Handlers; High-throughput screen; High-throughput screening; Immunoblotting; Kinases; Localization; Muscular dystrophy; Musculoskeletal system; Mutation; Myoblasts; Myotubes; Plasmids; Proteins; Rodents; Sarcolemma; Transcription; Sarcolemma; Sarcospan; C2C12; Duchenne muscular dystrophy; High-throughput screen; Small molecules; Drug discovery; Dystrophin; Felodipine
• ISSN: 2044-5040; 2044-5040
• DOI: 10.1186/s13395-019-0218-x

Duchenne muscular dystrophy (DMD) is caused by loss of sarcolemma connection to the extracellular matrix. Transgenic overexpression of the transmembrane protein sarcospan (SSPN) in the DMD mdx mouse model significantly reduces disease pathology by restoring membrane adhesion. Identifying SSPN-based therapies has the potential to benefit patients with DMD and other forms of muscular dystrophies caused by deficits in muscle cell adhesion. Standard cloning methods were used to generate C2C12 myoblasts stably transfected with a fluorescence reporter for human SSPN promoter activity. Assay development and screening were performed in a core facility using liquid handlers and imaging systems specialized for use with a 384-well microplate format. Drug-treated cells were analyzed for target gene expression using quantitative PCR and target protein expression using immunoblotting. We investigated the gene expression profiles of SSPN and its associated proteins during myoblast differentiation into myotubes, revealing an increase in expression after 3 days of differentiation. We created C2C12 muscle cells expressing an EGFP reporter for SSPN promoter activity and observed a comparable increase in reporter levels during differentiation. Assay conditions for high-throughput screening were optimized for a 384-well microplate format and a high-content imager for the visualization of reporter levels. We conducted a screen of 3200 compounds and identified seven hits, which include an overrepresentation of L-type calcium channel antagonists, suggesting that SSPN gene activity is sensitive to calcium. Further validation of a select hit revealed that the calcium channel inhibitor felodipine increased SSPN transcript and protein levels in both wild-type and dystrophin-deficient myotubes, without increasing differentiation. We developed a stable muscle cell line containing the promoter region of the human SSPN protein fused to a fluorescent reporter. Using the reporter cells, we created and validated a scalable, cell-based assay that is able to identify compounds that increase SSPN promoter reporter, transcript, and protein levels in wild-type and dystrophin-deficient muscle cells.